KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Evaluation of the Childhood Hodgkin International Prognostic Score (CHIPS) in High-Risk Pediatric Hodgkin Lymphoma Patients Treated on Children's Oncology Group AHOD1331.

Jennifer A Belsky, Lindsay A Renfro, Frank G Keller, David C Hodgson, Angela Punnett, Kathleen McCarten, Steve Y Cho, Yue Wu, Kara M Kelly, Sharon M Castellino, Cindy L Schwartz

Pediatr Blood Cancer 72(9) e31856

PMID40515508
PMCIDPMC12230980
DOI10.1002/pbc.31856
发表日期2025-06-14
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

BACKGROUND: CHIPS (Childhood Hodgkin International Prognostic Score), a predictive score for event-free-survival (EFS), was originally developed using factors presenting at diagnosis in patients with intermediate-risk Hodgkin lymphoma (HL). Prospective validation of CHIPS in patients was a pre-specified aim of AHOD1331, a trial comparing brentuximab-vedotin, doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide (Bv-AVEPC) to standard ABVE-PC (and response-adapted radiation) in children with high-risk HL. METHODS: AHOD1331 was a multicenter randomized phase 3 study. Patients were aged 2-21 years with untreated stages IIB+bulk, IIIB, IV HL. CHIPS was determined by assigning one point each for: Stage IV disease, large mediastinal adenopathy (greater than one-third thoracic diameter), albumin (<3.5 g/dL), and fever (T ≥ 38°C). Associations between CHIPS, baseline patient, and disease characteristics were tested. The validity of CHIPS to predict EFS was evaluated by both overall and within pre-specified subgroups defined by treatment arm, PET2 response, and disease stage. RESULTS: The four CHIPS components were analyzable in 576 of the 587 eligible patients. Distribution of CHIPS did not differ by study treatment arm (p = 0.158). CHIPS was significantly prognostic for EFS in this high-risk cohort (p = 0.008) and was independently predictive of EFS regardless of treatment arm, PET2 response, or stage. In subset analyses, CHIPS remained independently prognostic among patients with PET2 rapid responding lesions (RRL; p = 0.021) or Stage IVB disease (p = 0.047). CONCLUSION: CHIPS were predictive of EFS in patients with high-risk HL treated on AHOD1331. CHIPS may aid in the allocation of patients to risk-based treatment algorithms, and can serve as an effective, inexpensive, and feasible proxy for more biologically based factors.

KM 提取结果

2 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 2:

Event Free Survival by CHIPS within AHOD1331 Cohort

ABVE-PC_Arm

EFS

Figure 2: · Panel ABVE-PC_Arm

complete 待 EXE 对齐 预期 5 条 已提取 5 条

Panel ABVE-PC_Arm 是同一 Figure 2: 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:flat topline artifact
查看结果
KM Figure1 个面板

Figure 3:

Event Free Survival by CHIPS within PET2 Response Groups

A

EFS

Figure 3: · Panel A

complete 待 EXE 对齐 预期 5 条 已提取 5 条

Panel A 是同一 Figure 3: 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:flat topline artifact
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1:Overall Event Free Survival by CHIPS Score
非 KM Figure